Cargando…
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Background: Previously we identified a DNA damage response–deficient (DDRD) molecular subtype within breast cancer. A 44-gene assay identifying this subtype was validated as predicting benefit from DNA-damaging chemotherapy. This subtype was defined by interferon signaling. In this study, we address...
Autores principales: | Parkes, Eileen E., Walker, Steven M., Taggart, Laura E., McCabe, Nuala, Knight, Laura A., Wilkinson, Richard, McCloskey, Karen D., Buckley, Niamh E., Savage, Kienan I., Salto-Tellez, Manuel, McQuaid, Stephen, Harte, Mary T., Mullan, Paul B., Harkin, D. Paul, Kennedy, Richard D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441301/ https://www.ncbi.nlm.nih.gov/pubmed/27707838 http://dx.doi.org/10.1093/jnci/djw199 |
Ejemplares similares
-
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017) -
The clinical and molecular significance associated with STING signaling in breast cancer
por: Parkes, Eileen E., et al.
Publicado: (2021) -
Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention
por: Buckley, Niamh, et al.
Publicado: (2015) -
Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment
por: Buckley, Niamh E., et al.
Publicado: (2016) -
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy
por: Gilmore, Elaine, et al.
Publicado: (2019)